Moon Hee-Won, Yun Yeo-Min, Hur Mina, Park Jung Hwan, Lee Hae Won, Chang Seong-Hwan, Yun Ik Jin
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Korean J Lab Med. 2009 Dec;29(6):585-8. doi: 10.3343/kjlm.2009.29.6.585.
Due to an extreme shortage of cadaveric kidneys, many centers in Japan successfully performed ABO-incompatible kidney transplantations using plasmapheresis, splenectomy and immunosuppression. Recently, a protocol including anti-CD20 monoclonal antibody (rituximab) and antigen-selective immunoadsorption has been used for ABO-incompatible transplantation in Europe. In Korea, ABO-incompatible kidney transplantation has been rarely performed. We report an experience of successful ABO-incompatible kidney transplantation using plasmapheresis and rituximab. The patient was a 32-yr-old female suffering from chronic renal failure, and her blood type was O, Rh+. The donor was her husband, and his blood type was B, Rh+. A combination therapy including 5 times of plasmapheresis starting from 10 days before transplantation with 2-day interval, intravenous gammaglobulin, rituximab at 2 weeks before transplantation and potent immunosuppression successfully decreased the titers of anti-A and anti-B antibodies to 1:2 and 1:1, respectively. The kidney transplantation was successful without any sign of hyperacute or acute rejection.
由于尸体肾严重短缺,日本许多中心通过血浆置换、脾切除术和免疫抑制成功开展了ABO血型不相容肾移植。最近,欧洲采用了一种包括抗CD20单克隆抗体(利妥昔单抗)和抗原选择性免疫吸附的方案用于ABO血型不相容移植。在韩国,ABO血型不相容肾移植很少进行。我们报告了一例使用血浆置换和利妥昔单抗成功进行ABO血型不相容肾移植的经验。患者为一名32岁患慢性肾衰竭的女性,血型为O型,Rh阳性。供体是她的丈夫,血型为B型,Rh阳性。从移植前10天开始,每隔2天进行5次血浆置换,联合静脉注射丙种球蛋白、移植前2周使用利妥昔单抗以及强效免疫抑制,成功将抗A和抗B抗体效价分别降至1:2和1:1。肾移植成功,无任何超急性或急性排斥迹象。